NASDAQ: OCX - OncoCyte Corporation

Yield per half year: -28.72%
Sector: Healthcare

Share chart OncoCyte Corporation

Extended chart Simple chart
Financial Markets by TradingView

About

OncoCyte Corporation, a molecular diagnostics company, research, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. The company offers DetermaRx, a molecular test for early-stage adenocarcinoma of the lung; and DetermaIO, a proprietary gene expression assay. It also provides biomarker discovery testing, assay design and development, biopharma, and clinical trial support services, as well as various biomarker tests for pharmaceutical companies.

more details
The company has a collaboration agreement with Life Technologies Corporation to develop and collaborate in the commercialization of Oncomine Comprehensive Assay Plus and Determa IO assay for use with Ion Torrent Genexus integrated sequencer and purification system. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2016-01-04
ISIN US68235C1071
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://oncocyte.com
Цена ао 3
Change price per day: -0.939% (2.13)
Change price per week: -3.65% (2.19)
Change price per month: -13.35% (2.435)
Change price per 3 month: -26.74% (2.88)
Change price per half year: -28.72% (2.96)
Change price per year: -15.6% (2.5)
Change price per 3 year: -5.8% (2.24)
Change price per 5 year: +22.67% (1.72)
Change price per 10 year: 0% (2.11)
Change price per year to date: -15.6% (2.5)
All parameters

Underestimation

Title Value Grade
P/S 13.18 1
P/BV 0.7742 9
P/E 0 0
EV/EBITDA -0.6515 0
Total: 4.88

Efficiency

Title Value Grade
ROA, % -37.09 0
ROE, % -108.54 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -0.141 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 9293.75 10
Yield Ebitda, % 6.56 1
Yield EPS, % -58.31 0
Total: 3.6
More

Institutions Volume Share, %
Broadwood Capital, Inc. 2509066 30.37
AWM Investment Company, Inc. 754286 9.13
PURA VIDA INVESTMENTS, LLC 586930 7.11
Vanguard Group Inc 247873 3
Morgan Stanley 122973 1.49
Defender Capital, LLC 71650 0.87
Geode Capital Management, LLC 61482 0.74
Blackrock Inc. 60187 0.73
State Street Corporation 16289 0.2
Renaissance Technologies, LLC 12718 0.15

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Micro-Cap ETF 0.00668 13.79 1.54048



Head Job title Payment Year of birth
Mr. Joshua Riggs President, CEO & Director 504.63k 1983 (42 years)
Mr. James Liu Senior Director, Controller & Principal Accounting Officer 259.83k 1996 (29 years)
Dr. Ekkehard Schutz M.D., Ph.D. Chief Science Officer 409.27k
Mr. Yuh-Min Chiang Ph.D. Chief Technology Officer N/A
Dr. Michael D. West Ph.D. Scientific Advisor, Co-CEO of Biotime,Inc. & President of Biotime,Inc. N/A 1953 (72 years)
Mr. Peter Hong VP, General Counsel & Secretary N/A
Ms. Andrea Susan James Chief Financial Officer
Ms. Sandra O'Donald Senior Vice President of Business Operations

Address: United States, Irvine. CA, 15 Cushing - open in Google maps, open in Yandex maps
Website: https://oncocyte.com